VCP expression decrease as a biomarker of preclinical and early clinical stages of Parkinson's disease.
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
21 01 2020
21 01 2020
Historique:
received:
22
09
2019
accepted:
03
01
2020
entrez:
23
1
2020
pubmed:
23
1
2020
medline:
25
11
2020
Statut:
epublish
Résumé
Valosin-containing human protein (VCP) or p97 performs enzyme functions associated with the maintenance of protein homeostasis and control of protein quality. Disruption of its normal functioning might be associated with the development of Parkinson's disease (PD). Tissues of mice with toxin-induced presymptomatic and early symptomatic stages of PD, as well as 52 treated and untreated patients with newly diagnosed PD and nine patients with a "predicted" form of PD, were investigated. Significant changes in Vcp gene expression were observed in almost all studied mouse tissues. A significant decrease in VCP expression specific for PD was also detected at both the late preclinical and the early clinical stages of PD in untreated patients. Thus, a decrease in VCP expression is important for changes in the function of the nervous system at early stages of PD. Analysis of changes in VCP expression in all patients with PD and in Vcp in the peripheral blood of mice used as models of PD revealed significant decreases in expression specific for PD. These data suggest that a decrease in the relative levels of VCP mRNA might serve as a biomarker for the development of pathology at the early clinical and preclinical stages of human PD.
Identifiants
pubmed: 31964996
doi: 10.1038/s41598-020-57938-3
pii: 10.1038/s41598-020-57938-3
pmc: PMC6972783
doi:
Substances chimiques
Biomarkers
0
RNA, Messenger
0
VCP protein, human
EC 3.6.4.6
Valosin Containing Protein
EC 3.6.4.6
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
827Références
Rabouille, C., Levine, T. P., Peters, J. M. & Warren, G. An NSF-like ATPase, p97, and NSF mediate cisternal regrowth from mitotic Golgi fragments. Cell 82, 905–914 (1995).
doi: 10.1016/0092-8674(95)90270-8
Buchberger, A., Schindelin, H. & Hanzelmann, P. Control of p97 function by cofactor binding. FEBS Lett. 589, 2578–2589, https://doi.org/10.1016/j.febslet.2015.08.028 (2015).
doi: 10.1016/j.febslet.2015.08.028
pubmed: 26320413
Meyer, H., Bug, M. & Bremer, S. Emerging functions of the VCP/p97 AAA-ATPase in the ubiquitin system. Nat. Cell Biol. 14, 117–123, https://doi.org/10.1038/ncb2407 (2012).
doi: 10.1038/ncb2407
pubmed: 22298039
Christianson, J. C. & Ye, Y. Cleaning up in the endoplasmic reticulum: ubiquitin in charge. Nat. Struct. Mol. Biol. 21, 325–335, https://doi.org/10.1038/nsmb.2793 (2014).
doi: 10.1038/nsmb.2793
pubmed: 24699081
pmcid: 24699081
Ye, Y., Shibata, Y., Yun, C., Ron, D. & Rapoport, T. A. A membrane protein complex mediates retro-translocation from the ER lumen into the cytosol. Nat. 429, 841–847, https://doi.org/10.1038/nature02656 (2004).
doi: 10.1038/nature02656
Brandman, O. et al. A ribosome-bound quality control complex triggers degradation of nascent peptides and signals translation stress. Cell 151, 1042–1054, https://doi.org/10.1016/j.cell.2012.10.044 (2012).
doi: 10.1016/j.cell.2012.10.044
pubmed: 3534965
pmcid: 3534965
Defenouillère, Q. et al. Cdc48-associated complex bound to 60S particles is required for the clearance of aberrant translation products. Proc. Natl Acad. Sci. U S Am. 110, 5046–5051, https://doi.org/10.1073/pnas.1221724110 (2013).
doi: 10.1073/pnas.1221724110
Verma R O. R., Kolawa NJ, Deshaies RJ Cdc48/p97promotes degradation of aberrant nascent polypeptides bound to the ribosome. eLife 2 (2013).
Imamura, S., Yabu, T. & Yamashita, M. Protective role of cell division cycle 48 (CDC48) protein against neurodegeneration via ubiquitin-proteasome system dysfunction during zebrafish development. J. Biol. Chem. 287, 23047–23056, https://doi.org/10.1074/jbc.M111.332882 (2012).
doi: 10.1074/jbc.M111.332882
pubmed: 22549779
pmcid: 3391108
Watts, G. D. et al. Inclusion body myopathy associated with Paget disease of bone and frontotemporal dementia is caused by mutant valosin-containing protein. Nat. Genet. 36, 377–381, https://doi.org/10.1038/ng1332 (2004).
doi: 10.1038/ng1332
pubmed: 15034582
Kovach, M. J. et al. Clinical delineation and localization to chromosome 9p13.3-p12 of a unique dominant disorder in four families: hereditary inclusion body myopathy, Paget disease of bone, and frontotemporal dementia. Mol. Genet. Metab. 74, 458–475, https://doi.org/10.1006/mgme.2001.3256 (2001).
doi: 10.1006/mgme.2001.3256
pubmed: 11749051
pmcid: 6277059
Falcao de Campos, C. & de Carvalho, M. Distal myopathy and rapidly progressive dementia associated with a novel mutation in the VCP gene: Expanding inclusion body myopathy with early-onset Paget disease and frontotemporal dementia spectrum. Journal of clinical neuroscience: official journal of the Neurosurgical Society of Australasia, https://doi.org/10.1016/j.jocn.2019.03.063 (2019).
doi: 10.1016/j.jocn.2019.03.063
Gonzalez, M. A. et al. A novel mutation in VCP causes Charcot-Marie-Tooth Type 2 disease. Brain: a J. Neurol. 137, 2897–2902, https://doi.org/10.1093/brain/awu224 (2014).
doi: 10.1093/brain/awu224
Gonzalez-Perez, P. et al. Novel mutation in VCP gene causes atypical amyotrophic lateral sclerosis. Neurol. 79, 2201–2208, https://doi.org/10.1212/WNL.0b013e318275963b (2012).
doi: 10.1212/WNL.0b013e318275963b
Johnson, J. O. et al. Exome sequencing reveals VCP mutations as a cause of familial ALS. Neuron 68, 857–864, https://doi.org/10.1016/j.neuron.2010.11.036 (2010).
doi: 10.1016/j.neuron.2010.11.036
pubmed: 21145000
pmcid: 3032425
Nguyen, D. K. H., Thombre, R. & Wang, J. Autophagy as a Common Pathway in Amyotrophic Lateral Sclerosis. Neuroscience letters, https://doi.org/10.1016/j.neulet.2018.04.006 (2018).
doi: 10.1016/j.neulet.2018.04.006
Shi, Z. et al. Characterization of the Asian myopathy patients with VCP mutations. Eur. J. neurology: Off. J. Eur. Federation Neurological Societies 19, 501–509, https://doi.org/10.1111/j.1468-1331.2011.03575.x (2012).
doi: 10.1111/j.1468-1331.2011.03575.x
Fujimaki, M. et al. Parkinsonism in a patient with valosin-containing protein gene mutation showing: a case report. J. Neurol. 264, 1284–1286, https://doi.org/10.1007/s00415-017-8467-2 (2017).
doi: 10.1007/s00415-017-8467-2
pubmed: 28364293
Schroder, R. et al. Mutant valosin-containing protein causes a novel type of frontotemporal dementia. Ann. Neurol. 57, 457–461, https://doi.org/10.1002/ana.20407 (2005).
doi: 10.1002/ana.20407
pubmed: 15732117
Mehta, S. G. et al. Genotype-phenotype studies of VCP-associated inclusion body myopathy with Paget disease of bone and/or frontotemporal dementia. Clin. Genet. 83, 422–431, https://doi.org/10.1111/cge.12000 (2013).
doi: 10.1111/cge.12000
pubmed: 22909335
Hirtz, D. et al. How common are the "common" neurologic disorders? Neurol. 68, 326–337, https://doi.org/10.1212/01.wnl.0000252807.38124.a3 (2007).
doi: 10.1212/01.wnl.0000252807.38124.a3
Wong, S. L., Gilmour, H. & Ramage-Morin, P. L. Parkinson’s disease: Prevalence, diagnosis and impact. Health Rep. 25, 10–14 (2014).
pubmed: 25408491
Gasser, T. Molecular pathogenesis of Parkinson disease: insights from genetic studies. Expert. Rev. Mol. Med. 11, e22, https://doi.org/10.1017/S1462399409001148 (2009).
doi: 10.1017/S1462399409001148
pubmed: 19631006
Lesage, S. & Brice, A. Parkinson’s disease: from monogenic forms to genetic susceptibility factors. Hum. Mol. Genet. 18, R48–59, https://doi.org/10.1093/hmg/ddp012 (2009).
doi: 10.1093/hmg/ddp012
pubmed: 19297401
Braak, H. & Del Tredici, K. Neuropathological Staging of Brain Pathology in Sporadic Parkinson’s disease: Separating the Wheat from the Chaff. J. Parkinson’s Dis. 7, S71–S85, https://doi.org/10.3233/JPD-179001 (2017).
doi: 10.3233/JPD-179001
Nguyen, M., Wong, Y. C., Ysselstein, D., Severino, A. & Krainc, D. Synaptic, Mitochondrial, and Lysosomal Dysfunction in Parkinson’s Disease. Trends Neurosci. 42, 140–149, https://doi.org/10.1016/j.tins.2018.11.001 (2019).
doi: 10.1016/j.tins.2018.11.001
pubmed: 30509690
Hauser, M. A. et al. Expression Profiling of Substantia Nigra in Parkinson Disease, Progressive Supranuclear Palsy, and Frontotemporal Dementia With Parkinsonism. Arch. Neurol. 62, 917–921 (2005).
doi: 10.1001/archneur.62.6.917
Miller, R. M. et al. Robust dysregulation of gene expression in substantia nigra and striatum in Parkinson’s disease. Neurobiol. Dis. 21, 305–313, https://doi.org/10.1016/j.nbd.2005.07.010 (2006).
doi: 10.1016/j.nbd.2005.07.010
pubmed: 16143538
Bossers, K. et al. Analysis of Gene Expression in Parkinson’s Disease: Possible Involvement of Neurotrophic Support and Axon Guidance in Dopaminergic Cell Death. Brain Pathol. 19, 91–107 (2009).
doi: 10.1111/j.1750-3639.2008.00171.x
Glaab, E. & Schneider, R. Comparative pathway and network analysis of brain transcriptome changes during adult aging and in Parkinson’s disease. Neurobiol. Dis. 74, 1–13, https://doi.org/10.1016/j.nbd.2014.11.002 (2015).
doi: 10.1016/j.nbd.2014.11.002
pubmed: 25447234
Simunovic, F. et al. Gene expression profiling of substantia nigra dopamine neurons: further insights into Parkinson’s disease pathology. Brain: a J. Neurol. 132, 1795–1809, https://doi.org/10.1093/brain/awn323 (2009).
doi: 10.1093/brain/awn323
Grünblatt, E. et al. Gene expression profiling of parkinsonian substantia nigra pars compacta; alterations in ubiquitin-proteasome, heat shock protein, iron and oxidative stress regulated proteins, cell adhesion/cellular matrix and vesicle trafficking genes. J. neural Transm. 111, 1543–1573, https://doi.org/10.1007/s00702-004-0212-1 (2004).
doi: 10.1007/s00702-004-0212-1
pubmed: 15455214
Coppede, F. Genetics and epigenetics of Parkinson’s disease. TheScientificWorldJournal 2012, 489830, https://doi.org/10.1100/2012/489830 (2012).
doi: 10.1100/2012/489830
pubmed: 22623900
pmcid: 3353471
Lesage, S. & Brice, A. Role of mendelian genes in "sporadic" Parkinson’s disease. Parkinsonism Relat. Disord. 18(Suppl 1), S66–70, https://doi.org/10.1016/S1353-8020(11)70022-0 (2012).
doi: 10.1016/S1353-8020(11)70022-0
pubmed: 22166458
Ugrumov, M. V. et al. Modeling of presymptomatic and symptomatic stages of parkinsonism in mice. Neurosci. 181, 175–188, https://doi.org/10.1016/j.neuroscience.2011.03.007 (2011).
doi: 10.1016/j.neuroscience.2011.03.007
Kolacheva, A. A., Kozina, E. A., Volina, E. V. & Ugryumov, M. V. Time course of degeneration of dopaminergic neurons and respective compensatory processes in the nigrostriatal system in mice. Doklady Biol. Sci.: Proc. Acad. Sci. USSR, Biol. sciences Sect. / translated Russian 456, 160–164, https://doi.org/10.1134/s0012496614030041 (2014).
doi: 10.1134/s0012496614030041
Braak, H., Ghebremedhin, E., Rub, U., Bratzke, H. & Del Tredici, K. Stages in the development of Parkinson’s disease-related pathology. Cell tissue Res. 318, 121–134, https://doi.org/10.1007/s00441-004-0956-9 (2004).
doi: 10.1007/s00441-004-0956-9
pubmed: 15338272
Braak, H. et al. Pathology associated with sporadic Parkinson’s disease–where does it end? Journal of neural transmission. Supplementum, 89-97 (2006).
German, D. C. et al. The neurotoxin MPTP causes degeneration of specific nucleus A8, A9 and A10 dopaminergic neurons in the mouse. Neurodegeneration: a J. neurodegenerative disorders, neuroprotection, neuroregeneration 5, 299–312, https://doi.org/10.1006/neur.1996.0041 (1996).
doi: 10.1006/neur.1996.0041
Meredith, G. E., Totterdell, S., Potashkin, J. A. & Surmeier, D. J. Modeling PD pathogenesis in mice: advantages of a chronic MPTP protocol. Parkinsonism Relat. Disord. 14(Suppl 2), S112–115, https://doi.org/10.1016/j.parkreldis.2008.04.012 (2008).
doi: 10.1016/j.parkreldis.2008.04.012
pubmed: 18585085
pmcid: 2547123
Gerlach, M. & Riederer, P. Animal models of Parkinson’s disease: an empirical comparison with the phenomenology of the disease in man. J. neural Transm. 103, 987–1041 (1996).
doi: 10.1007/BF01291788
Przedborski, S. et al. The parkinsonian toxin MPTP: action and mechanism. Restor. Neurol. Neurosci. 16, 135–142 (2000).
pubmed: 12671216
Langston, J. W. et al. Evidence of active nerve cell degeneration in the substantia nigra of humans years after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine exposure. Ann. Neurol. 46, 598–605 (1999).
doi: 10.1002/1531-8249(199910)46:4<598::AID-ANA7>3.0.CO;2-F
Schneider, S. A. & Obeso, J. A. Clinical and pathological features of Parkinson’s disease. Curr. Top. Behav. Neurosci. 22, 205–220, https://doi.org/10.1007/7854_2014_317 (2015).
doi: 10.1007/7854_2014_317
pubmed: 24850081
Cheng, H. C., Ulane, C. M. & Burke, R. E. Clinical progression in Parkinson disease and the neurobiology of axons. Ann. Neurol. 67, 715–725, https://doi.org/10.1002/ana.21995 (2010).
doi: 10.1002/ana.21995
pubmed: 20517933
pmcid: 2918373
Sterling, N. W. et al. Striatal shape in Parkinson’s disease. Neurobiol. aging 34, 2510–2516, https://doi.org/10.1016/j.neurobiolaging.2013.05.017 (2013).
doi: 10.1016/j.neurobiolaging.2013.05.017
pubmed: 23820588
pmcid: 3742686
Alieva, A. K. et al. Transcriptome Profile Changes in Mice with MPTP-Induced Early Stages of Parkinson’s Disease. Mol. Neurobiol. 54, 6775–6784, https://doi.org/10.1007/s12035-016-0190-y (2017).
doi: 10.1007/s12035-016-0190-y
pubmed: 27757834
Nagai, Y. et al. Decrease of the D3 dopamine receptor mRNA expression in lymphocytes from patients with Parkinson’s disease. Neurol. 46, 791–795, https://doi.org/10.1212/wnl.46.3.791 (1996).
doi: 10.1212/wnl.46.3.791
Barbanti, P. et al. Increased expression of dopamine receptors on lymphocytes in Parkinson’s disease. Mov. disorders: Off. J. Mov. Disord. Soc. 14, 764–771 (1999).
doi: 10.1002/1531-8257(199909)14:5<764::AID-MDS1008>3.0.CO;2-W
Buttarelli, F. R. et al. Central and peripheral dopamine transporter reduction in Parkinson’s disease. Neurol. Res. 31, 687–691 (2009).
doi: 10.1179/174313209X383259
The guide for the care and use of laboratory animals. (8th ed. Washington (DC): National Academies Press, 2011).
Fahn, B. S., R. Elton, M.o.t.U.D. Committee. Unified Parkinson’s Disease rating scale. Recent developments in Parkinson’s disease. Florham Park, NY, Macmillan Health Care Information (1987).
Goetz, C. G. et al. Movement Disorder Society Task Force report on the Hoehn and Yahr staging scale: status and recommendations. Mov. disorders: Off. J. Mov. Disord. Soc. 19, 1020–1028, https://doi.org/10.1002/mds.20213 (2004).
doi: 10.1002/mds.20213
Hughes, A. J., Daniel, S. E., Kilford, L. & Lees, A. J. Accuracy of clinical diagnosis of idiopathic Parkinson’s disease: a clinico-pathological study of 100 cases. J. neurology, neurosurgery, psychiatry 55, 181–184 (1992).
doi: 10.1136/jnnp.55.3.181
Suslov, O. & Steindler, D. A. PCR inhibition by reverse transcriptase leads to an overestimation of amplification efficiency. Nucleic Acids Res 33, https://doi.org/10.1093/nar/gni176 (2005).
doi: 10.1093/nar/gni176
GelQuant.NET, http://biochemlabsolutions.com/GelQuantNET.html .
NCBI Database, https://www.ncbi.nlm.nih.gov/.
Primer3, http://bioinfo.ut.ee/primer3 .
Primer-BLAST, https://www.ncbi.nlm.nih.gov/tools/primer-blast/.
Livak, K. J. & Schmittgen, T. D. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 25, 402–408, https://doi.org/10.1006/meth.2001.1262 (2001).
doi: 10.1006/meth.2001.1262
pubmed: 11846609
pmcid: 11846609
Statistica, < https://en.freedownloadmanager.org/Windows-PC/STATISTICA.html >
Hettne, K. M. et al. The Implicitome: A Resource for Rationalizing Gene-Disease Associations. PLoS one 11, e0149621, https://doi.org/10.1371/journal.pone.0149621 (2016).
doi: 10.1371/journal.pone.0149621
pubmed: 26919047
pmcid: 4769089
Au, W. L., Adams, J. R., Troiano, A. R. & Stoessl, A. J. Parkinson’s disease: In vivo assessment of disease progression using positron emission tomography. Brain Res. Mol. brain research 134, 24–33 (2005).
doi: 10.1016/j.molbrainres.2004.09.028